ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ALZN Alzamend Neuro Inc

0.70
-0.0092 (-1.30%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Alzamend Neuro Inc ALZN NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.0092 -1.30% 0.70 10:00:00
Open Price Low Price High Price Close Price Previous Close
0.72 0.70 0.73 0.70 0.7092
more quote information »

Recent News

Date Time Source Heading
08/3/202408:30EDGAR2Form 8-K - Current report
03/2/202408:30EDGAR2Form 8-K - Current report
06/1/202408:30EDGAR2Form 8-K - Current report
16/12/202308:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/12/202300:00BWAlzamend Neuro Receives FDA “Study May Proceed” Notification..
21/11/202300:00BWAlzamend Neuro Receives FDA “Study May Proceed” Notification..
17/11/202308:30EDGAR2Form 8-K - Current report
17/11/202300:00BWAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid..
14/11/202300:00BWAlzamend Neuro Submits IND Application for a Phase IIA..
31/10/202307:30EDGAR2Form 8-K - Current report
30/10/202323:00BWAlzamend Neuro Announces Reverse Stock Split
23/10/202323:00BWAlzamend Neuro Submits IND Application for a Phase IIA..
02/10/202323:00BWAlzamend Neuro Receives FDA “Study May Proceed” Notification..
30/9/202306:30EDGAR2Form 8-K - Current report
27/9/202308:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/9/202306:30EDGAR2Form 8-K - Current report
22/9/202322:00BWAlzamend Neuro Granted Extension by Nasdaq Panel to Regain..
14/9/202307:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/9/202307:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09/9/202307:00EDGAR2Form 8-K - Current report
02/9/202306:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
30/8/202322:00BWAlzamend Neuro Submits IND Application for Phase IIA..
25/8/202306:30EDGAR2Form DEF 14A - Other definitive proxy statements
17/8/202306:30EDGAR2Form 8-K - Current report
11/8/202314:15EDGAR2Form EFFECT - Notice of Effectiveness
11/8/202306:30EDGAR2Form PRE 14A - Other preliminary proxy statements
08/8/202306:30EDGAR2Form 8-K - Current report
03/8/202306:31EDGAR2Form S-3 - Registration statement under Securities Act of..
28/7/202306:56EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22/6/202322:00BWAlzamend Neuro Announces Positive Phase IIA Clinical Trial..
13/6/202322:00BWAlzamend Neuro CEO Stephan Jackman to Participate on the..

Your Recent History

Delayed Upgrade Clock